Immunity Theme News Today

A landmark trial in The Gambia found the patches - which painlessly penetrate the skin - were just as effective as injections against measles and rubella.

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that painlessly penetrate the skin and deliver the vaccine, or by conventional injection with a needle and syringe.

The first study of the use of microarray patches to vaccinate children has shown that the method is safe and induces strong immune responses.The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that painlessly penetrate the skin and deliver the vaccine, or by conventional injection with a needle and syringe.

The rollout of Men5CV, a 5-in-1 vaccine to protect against five strains of meningitis, has started in Nigeria, according to an announcement made by the World Health Organization (WHO).Meningitis is a serious infection that leads to inflammation of the membranes that surround and protect the brain and spinal cord. Although research has shown that the disease is largely preventable with proper vaccination, last year there was a 50% jump in annual meningitis cases reported across Africa.

Roy Robins-Browne’s profile on The Conversation

Pentavalent vaccine was found effective against five of the six meningococcal bacteria strains found in Africa.

A trial of a new vaccine against meningococcal disease, a cause of meningitis and blood poisoning, has found that it is safe and induces a strong immune response across five strains of meningococcal bacteria: A, C, W, Y and X. The phase 3 trial compared the immune response generated by the new pentavalent vaccine NmCV-5 against that of the licensed quadrivalent MenACWY-D vaccine in 1,800 healthy 2-29-year-olds in Mali and The Gambia.

A trial investigating a new vaccine targeting meningococcal disease, a leading cause of meningitis and blood poisoning, has concluded that the vaccine is

A trial of a new vaccine against meningococcal disease, a cause of meningitis and blood poisoning, has found that it is safe and induces a strong immune response across five strains of meningococcal bacteria: A, C, W, Y and X.

The third day of World Immunisation Week will concentrate on Tuberculosis, focusing on vaccine development, progress, equity and clinical trials. The webinar, chaired by Toyin Togun from LSHTM, will include a presentation by Jayne Sutherland from LSHTM on TB vaccine development and Richard White from LSHTM on the contribution of TB vaccines to global TB control.